Ajooni Biotech Limited has announced a board meeting to review the financial results for the quarter and half-year.

For the quarter ended December 31, 2024, the company reported revenue from operations of ₹2,572.44 crore and a net profit of ₹73.02 crore.

Total income from operations was ₹2,603.40 crore with total expenses of ₹2,523.93 crore.

The current asset base stands at ₹9,366.94 crore, while total equity is ₹8,733.75 crore.

This financial performance reflects solid growth and efficiency, likely fostering a positive outlook among investors, though vigilance is warranted due to market volatility.